United Therapeutics at a Glance
United Therapeutics at a Glance
WHAT IS UNITED THERAPEUTICS?
United Therapeutics is a profitable, 25-year old, $9B+ market cap, dare-to-be-different biotechnology company that is building on its expertise and success developing therapies for PAH to address other chronic, life-threatening medical conditions ranging from pulmonary fibrosis, to pediatric cancer, to organ manufacturing and transplantation. Our profit margins are among the strongest in the entire biotechnology industry.
WHAT DID WE DO IN 2020?
We continued to deliver strong operating results from our four PAH therapies and our pediatric cancer treatment, yielding revenues of ~$1.5 billion and net income of over $500 million. But this solid result was by no means a given.
Like many companies, we felt the impact of the COVID-19 pandemic. It delayed the launch of the Remunity® Pump for Remodulin® until February 2021. Enrollment of our clinical trials was temporarily paused as hospitals shut down. We felt pressure on our revenues, as it became difficult for patients to start advanced therapies, and our staff was limited to virtual interactions with healthcare providers. Our product development teams, however, quickly found ways to adapt clinical trial protocols and expand clinical site activation efforts, and we worked hard to ensure patients had uninterrupted access to our therapies.
We obtained approval of the Remunity Pump for Remodulin in 2020, and launched the product in February 2021. We believe this product will help us maintain and grow Remodulin revenues going forward. We submitted a supplemental new drug application for Tyvaso® in patients with pulmonary hypertension due to interstitial lung disease (PH-ILD), which the FDA approved in March 2021 following the results of an exciting study published in the New England Journal of Medicine.
We also continued to listen to our shareholders — twice reaching out to those representing over 70% of our shares to offer engagement with our Board members — and steadily increased the detailed information we provide on our sustainability efforts, Board refreshment, and compensation practices. And we amended our certificate of incorporation to begin the destaggering of our Board of Directors.
HOW DID WE DO IN 2020?
Our solid 2020 results in the midst of a pandemic are a testament to the value of our focus on being a built-to-last, long-focused, and people-focused company. Successful R&D efforts led to a return to revenue growth in 2020, and strong revenues coupled with conservative budgeting generated substantial free cash flow. These contributed to our strong financial condition, including $3.0 billion in cash, cash equivalents, and marketable securities as of December 31, 2020 ($2.2 billion net of $800 million in indebtedness).
This execution led to a significant rebound in our stock price. During 2020, our stock price grew by 72%, outperforming the 26% return generated by the Nasdaq Biotechnology Index.
WHERE ARE WE HEADING?
In addition to the already-launched label expansion for Tyvaso in PH-ILD and the Remunity Pump for Remodulin, both in 2021, we are striving toward additional potential product approvals/launches such as Tyvaso DPI™ and the Implantable System for Remodulin.
We expect to continue to grow revenue from our treprostinil-based therapies through label expansions, new indications, new formulations, and the introduction of new delivery devices. We are also working on a number of entirely new therapies to treat PAH and other rare diseases that we hope to launch over the next several years. Longer-term, we have set the ambitious goal of solving the acute shortage of transplantable organs through our innovative organ manufacturing programs, including ex-vivo lung perfusion, xenotransplantation, regenerative medicine, and organ printing.
Our conservative balance sheet not only places our company in a very strong position to weather successfully the continued economic effects of the pandemic, but also gives us strategic flexibility to continue to seek out and drive down "corridors of indifference" to help patients with PAH and other orphan lung diseases in need.
Finally, we started the process, which we hope our shareholders will approve later in 2021, to amend our charter to become a Delaware public benefit corporation, which is already the legal status of our subsidiary Lung Biotechnology PBC. We believe this step will align our charter with our existing values and operating model.
2 United Therapeutics